University of Ulster

Hussain, AI, Anwar, F, Chatha, SAS, Latif, S, Sherazi, STH, Ahmad, A, Worthington, Jenny and Sarker, SD (2013) Chemical composition and bioactivity studies of the essential oils from two Thymus species from the Pakistani flora. LWT- Food Science and Technology, 50 (1). pp. 185-192.

Yakkundi, A, McCallum, L, O'Kane, A, Dyer, H, Worthington, Jenny, McKeen, H, McClements , L, Elliott, C, McCarthy, HO, Hirst, DG and Robson, T (2013) The anti-migratory effects of FKBPL and its peptide derivative AD-01: Regulation of CD44 and the cytoskeltal pathway.. PLOS One, 8 (2).

Ming, L, Byrne, N, Camac, SN, Ward, C, Mitchell, Christopher, Waugh, D, McKeown, Stephanie and Worthington, Jenny (2013) Androgen deprivation results in time-dependent hypoxia in LNCaP prostate tumours; informed scheduling of the bioreductive drug AQ4N improves treatment response.. International Journal of Cancer, 132. pp. 1323-1332.

Browne, G, Nesbitt, H, Ming, L, Stein, GS, Lian, JB, McKeown, SR and Worthington, Jenny (2012) Bicalutamide-induced hypoxia potentiates RUNX2-mediated Bcl-2 expression resulting in apoptosis resistance. . British Journal of Cancer, 107. pp. 1714-1721.

Worthington, Jenny, McKeown, Stephanie and Banat, Ibrahim (2011) A study of anti-cancer effects of Funalia trogii in vitro and in vivo. Food and Chemical Toxicology, 49 (7). pp. 1477-1483.

Valentine, A., O'Rourke, M, Yakkundi, A, Worthington, Jenny, Hookham, M, Bicknall, R, McCarthy , HO, McClelland, K, McCallum, L, Dyer, H, McKeen, H, Waugh, DJ, Roberts, J, McGregor, J, Cotton, G, James, I, Harrison, T, Hirst, DG and Robson, T (2011) FKBPL and Peptide Derivatives: Novel Biological AgentsThat Inhibit Angiogenesis by a CD44-Dependent Mechanism. Clinical Cancer Research, 17 (5). pp. 1044-1056.

Adams, Catherine, McCarthy, Helen O., Coulter, Jonathan A., Worthington, Jenny, Murphy, Claire, Robson, Tracy and Hirst, Davi G. (2009) Nitric oxide synthase gene therapy enhances the toxicity of cisplatin in cancer cells. JOURNAL OF GENE MEDICINE, 11 (2). pp. 160-168.

Worthington, Jenny and Rashid, Shazia (2009) The therapeutic potential of mushroom extracts.. In: Natural Products as future therapeutic agents. Old City Publishing, pp. 49-72. ISBN 978-81-7895-394-6

Wilson, C, Scullin, P, Worthington, Jenny, Seaton, A, Maxwell, P, O'Rourke, D, Johnston, PG, McKeown, Stephanie, Wilson, RH, O'Sullivan, JM and Waugh, DJJ (2008) Dexamethasone potentiates the antiangiogenic activity of docetaxel in castration-resistant prostate cancer. BRITISH JOURNAL OF CANCER, 99 (12). pp. 2054-2064.

Marignol, L., Robson, T., McCarthy, H. O., Worthington, Jenny, Murray, M. M., Hollywood, D., Lawler, M. and Hirst, D. G. (2008) The tissue plasminogen activator gene promoter: a novel tool for radiogenic gene therapy of the prostate?. JOURNAL OF GENE MEDICINE, 10 (9). pp. 1032-1038.

Butterworth, Karl T, McCarthy, Helen O, Devlin, Andrea, Ming, Louise, Robson, Tracy, McKeown, Stephanie and Worthington, Jenny (2008) Hypoxia selects for androgen independent LNCaP cells with a more malignant geno- and phenotype. INTERNATIONAL JOURNAL OF CANCER, 123 (4). pp. 760-768.

Coulter, J. A., McCarthy, H. O., Worthington, Jenny, Robson, T., Scott, S. and Hirst, D. G. (2008) The radiation-inducible pE9 promoter driving inducible nitric oxide synthase radiosensitizes hypoxic tumour cells to radiation. GENE THERAPY, 15 (7). pp. 495-503.

O'Rourke, Martin, Ward, Claire, Worthington, Jenny, McKenna, Julie, Valentine, Andrea, Robson, Tracy, Hirst, David G and McKeown, Stephanie (2008) Evaluation of the antiangiogenic potential of AQ4N. CLINICAL CANCER RESEARCH, 14 (5). pp. 1502-1509.

McCarthy, Helen O., Coulter, Jonathan A., Worthington, Jenny, Robson, Tracy and Hirst, David G. (2007) Human osteocalcin: a strong promoter for nitric oxide synthase gene therapy, with specificity for hormone refractory prostate cancer. JOURNAL OF GENE MEDICINE, 9 (6). pp. 511-520.

McCarthy, HO, Worthington, Jenny, Barrett, E, Cosimo, E, Boyd, M, Mairs, RJ, Ward, C, McKeown, Stephanie, Hirst, DG and Robson, T (2007) p(21(WAF1))-mediated transcriptional targeting of inducible nitric oxide synthase gene therapy sensitizes tumours to fractionated radiotherapy. GENE THERAPY, 14 (3). pp. 246-255.

Worthington, J, Robson, T, Scott, S and Hirst, D (2005) Evaluation of a synthetic CArG promoter for nitric oxide synthase gene therapy of cancer. GENE THERAPY, 12 (19). pp. 1417-1423.

Robson, T, Worthington, Jenny, McKeown, Stephanie and Hirst, DG (2005) Radiogenic therapy: Novel approaches for enhancing tumor radiosensitivity. TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 4 (4). pp. 343-361.

McCarthy, HO, Worthington, Jenny, Ward, C, Barrett, E, Hirst, DG, McKeown, Stephanie and Robson, T (2004) Use of the p2l/WAF1 promoter for transcriptional targetting in cancer gene therapy. JOURNAL OF GENE MEDICINE, 6 (9). pp. 78.

Worthington, Jenny, McCarthy, HO, Barrett, E, Adams, C, Robson, T and Hirst, DG (2004) Use of the radiation-inducible WAF1 promoter to drive iNOS gene therapy as a novel anti-cancer treatment. JOURNAL OF GENE MEDICINE, 6 (6). pp. 673-680.

Worthington, Jenny, Robson, T, O'Keeffe, M and Hirst, DG (2002) Tumour cell radiosensitization using constitutive (CMV) and radiation inducible (WAF1) promoters to drive the iNOS gene: a novel suicide gene therapy. GENE THERAPY, 9 (4). pp. 263-269.

Worthington, Jenny, Robson, T, Murray, M, O'Rourke, M, Keilty, G and Hirst, DG (2000) Modification of vascular tone using iNOS under the control of a radiation-inducible promoter. GENE THERAPY, 7 (13). pp. 1126-1131.